A Phase 3 interventional study of Velaglucerase beta in Gaucher Disease, Gaucher Disease Type 1 and Gaucher Disease Type 3, sponsored by CANbridge Life Sciences Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 2 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by CANbridge Life Sciences Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Gaucher Disease with a site in China — 7 open to participants now, 9 under way, 2 of them phase 3. Gaucher Disease · China.
Among the 13 studies in Gaucher Disease with a site in China, this one is the 8th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2026, is one of 4 in phase 3, and was the 13th registered.
177 studies on the registry are indexed under Gaucher Disease; 41 are open to participants now.
Browse Gaucher Disease studies →7 of the 13 studies in Gaucher Disease with a site in China are open now. Recruiting first, the newest first:
Lingyi Biotech Co., Ltd. · Sites in China
Ages 18–60
He Huang · Sites in China
Ages 18–60
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 0 mo–24 mo
Genzyme, a Sanofi Company · Sites in China, United States, Argentina and 49 more countries
Shenzhen Geno-Immune Medical Institute · Sites in China
Ages 1–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 26 Gaucher Disease studies recruiting now, 11 (42%) set no upper age limit and 11 (42%) stop at 75 or younger; 15 take children under 18; 4 take healthy volunteers.
This study: 2 Years to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4 · Phase 3 4 · Phase 4 1
First in 1991; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 10 is below the median of 20 across 100 interventional studies indexed under Gaucher Disease.
Median enrollment 12 across the 12 interventional studies, 12,000 across the 1 observational. Of the 3 that completed or were terminated, 2 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 13 have an industry lead sponsor. The 10 most frequent:
CANbridge Life Sciences Ltd. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
CANbridge Life Sciences Ltd. has 1 study filed under Gaucher Disease — fewer than ten, so there is no comparison to draw.
3 of the studies in Gaucher Disease with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06162338He HuangA Study of the Safety and Preliminary Efficacy of LY-M001 Injection in the Treatment of Adult Patients with Gaucher Disease Type I | 2026-12-17 |
| NCT06528080Shanghai Jiao Tong University School of MedicineA Clinical Study for the Treatment of Pediatric and Adolescent Patients With Type 1 Gaucher Disease | 2027-05-30 |
| NCT06818838Lingyi Biotech Co., Ltd.A Clinical Study Evaluating LY-M001 Injection in the Treatment of Adult Patients With Type I Gaucher Disease | 2027-07-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 13 studies in Gaucher Disease with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, multicenter, open-label, single-arm study to evaluate the safety, efficacy, PK, PD, and immunogenicity of velaglucerase beta in untreated children with GD1 or GD3 for 39 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject has GD-related splenomegaly, defined as at least 2 to 3 cm below the left costal margin by palpation, and one or more of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is a single-arm study. All subjects will receive velaglucerase beta 60 U/kg IV Q2W for 37 weeks.
Drug: Velaglucerase beta
All subjects will receive velaglucerase beta 60 U/kg IV Q2W for 37 weeks with two weeks of follow-up through Week 39 (9 months).
Primary Endpoints
Incidence and number of TEAE, characterized by type, severity, seriousness (SAE), and relatedness to velaglucerase
Time frame: From Baseline to Week 39
Mean percent change in MN spleen volume
Normal spleen volume = 0.2% body weight. Multiples of normal (MN) spleen volume= actual MRI testing volume / normal spleen volume
Time frame: From Baseline to Week 39
Mean change in hemoglobin concentration (g/dL)
Time frame: From baseline to Week 39
Mean percent change in MN liver volume
Normal liver volume = 2.5% body weight. Multiples of normal (MN) liver volume= actual MRI testing volume / normal liver volume
Time frame: From Baseline to Week 39
Mean percent change in platelet count ( 10^9/L)
Time frame: From Baseline to Week 39
Mean change in height Z-score
Time frame: From Baseline to Week 39
Mean change in weight Z-score
Time frame: From Baseline to Week 39
Plan to share: Yes — only IPD used in the results publication
Supporting information: Study protocol, Statistical analysis plan
Time frame: Beginning 3 months and ending 3 years after the publication of results
Access criteria: The criteria that must be met the types of analyses that qualify for data sharing. A proposal that describes planned analyses must be submitted.
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Feb 2028, 17 months later.
Of 11 phase 3 interventional studies under Gaucher Disease, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 57. This study's planned 17 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CANbridge Life Sciences Ltd.